case_images: PMC4424725_01
case_images: Therapeutic trend of our patient with extensive primary acquired melanosis (PAM) in the left eye treated with topical mitomycin C (MMC) and interferon (INF) alpha-2b; (a-c), appearance of the eye at presentation: Histologically confirmed PAM with atypia involved the bulbar and palpebral conjunctiva as well as the superotemporal cornea; (d-f), relative response to therapy in the middle of the treatment, note decreased size and pigmentation of the lesion; (g-i), Final result of treatment after receiving MMC followed by 6 months of therapy with INF-alpha2b; (j-l), Appearance of the ocular surface after another year of follow-up, note more significant dilution of residual pigmentation without treatment.
case_images: JOVR-10-84-g001.jpg
case_images: PMC4424725_01_JOVR-10-84-g001.jpg
case_images: F1
case_images: Map biopsy confirmed PAM with atypia especially in the nodular part of the lesion [Figure 1a-c]. The lesion decreased in size and pigmentation in the middle of the second course of therapy [Figure 1d-f]. Thus, IFN-alpha2b (1 million units/ml) eye drops were initiated every 6 h for 6 months, during which no significant topical or systemic side effect occurred [Figure 1d-f]. No significant complications and no recurrence of the tumor were noted over 24 months follow-up [Figure 1g-l].